Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

CompletedOBSERVATIONAL
Enrollment

472

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Arthroplasty, ReplacementThromboembolism
Trial Locations (53)

Unknown

1160.84.4301 Boehringer Ingelheim Investigational Site, Vienna

1160.84.4310 Boehringer Ingelheim Investigational Site, Vienna

1160.84.3311 Boehringer Ingelheim Investigational Site, Angers

1160.84.3334 Boehringer Ingelheim Investigational Site, Bordeaux

1160.84.3303 Boehringer Ingelheim Investigational Site, Caen

1160.84.3314 Boehringer Ingelheim Investigational Site, Clermont-Ferrand

1160.84.3320 Boehringer Ingelheim Investigational Site, Créteil

1160.84.3307 Boehringer Ingelheim Investigational Site, Dijon Cédex

1160.84.3310 Boehringer Ingelheim Investigational Site, Illkirch-Graffenstaden

1160.84.3335 Boehringer Ingelheim Investigational Site, Le Havre

1160.84.3326 Boehringer Ingelheim Investigational Site, Les Lilas

1160.84.3312 Boehringer Ingelheim Investigational Site, Lyon

1160.84.3305 Boehringer Ingelheim Investigational Site, Marseille

1160.84.3323 Boehringer Ingelheim Investigational Site, Nantes Cédex 2

1160.84.3302 Boehringer Ingelheim Investigational Site, Paris

1160.84.3306 Boehringer Ingelheim Investigational Site, Paris

1160.84.3313 Boehringer Ingelheim Investigational Site, Pierre-Bénite

1160.84.3324 Boehringer Ingelheim Investigational Site, Poitiers Cédex

1160.84.3322 Boehringer Ingelheim Investigational Site, Saint Etienne Cédex 2

1160.84.3319 Boehringer Ingelheim Investigational Site, Saint-Saulve

1160.84.3316 Boehringer Ingelheim Investigational Site, Toulouse Cédex 9

1160.84.3332 Boehringer Ingelheim Investigational Site, Vannes Cédex

1160.84.04903 Boehringer Ingelheim Investigational Site, Berlin

1160.84.04947 Boehringer Ingelheim Investigational Site, Erlangen

1160.84.4922 Boehringer Ingelheim Investigational Site, Gelnhausen

1160.84.04927 Boehringer Ingelheim Investigational Site, Hachenburg

1160.84.04929 Boehringer Ingelheim Investigational Site, Koblenz

1160.84.04902 Boehringer Ingelheim Investigational Site, Marburg

1160.84.04946 Boehringer Ingelheim Investigational Site, München

1160.84.04913 Boehringer Ingelheim Investigational Site, Olsberg

1160.84.04914 Boehringer Ingelheim Investigational Site, Sylt

1160.84.04938 Boehringer Ingelheim Investigational Site, Wismar

1160.84.04948 Boehringer Ingelheim Investigational Site, Würzburg

1160.84.03908 Boehringer Ingelheim Investigational Site, Latina

1160.84.03902 Boehringer Ingelheim Investigational Site, Milan

1160.84.03904 Boehringer Ingelheim Investigational Site, Monza

1160.84.03909 Boehringer Ingelheim Investigational Site, Udine

1160.84.3409 Boehringer Ingelheim Investigational Site, Badalona (Barcelona)

1160.84.3410 Boehringer Ingelheim Investigational Site, Barcelona

1160.84.3403 Boehringer Ingelheim Investigational Site, Madrid

1160.84.3405 Boehringer Ingelheim Investigational Site, Málaga

1160.84.3404 Boehringer Ingelheim Investigational Site, Pamplona

1160.84.3412 Boehringer Ingelheim Investigational Site, Pozuelo de Alarcón - Madrid

1160.84.3401 Boehringer Ingelheim Investigational Site, Valencia

1160.84.3402 Boehringer Ingelheim Investigational Site, Zaragoza

1160.84.4603 Boehringer Ingelheim Investigational Site, Kungälv

1160.84.4601 Boehringer Ingelheim Investigational Site, Motala

1160.84.4604 Boehringer Ingelheim Investigational Site, Sollefteå

1160.84.04405 Boehringer Ingelheim Investigational Site, Basildon

1160.84.04408 Boehringer Ingelheim Investigational Site, Bedford

1160.84.04403 Boehringer Ingelheim Investigational Site, Luton

1160.84.04401 Boehringer Ingelheim Investigational Site, Wigan

1160.84.04407 Boehringer Ingelheim Investigational Site, Yeovil

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00847301 - Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery | Biotech Hunter | Biotech Hunter